| Literature DB >> 34086064 |
Jinghui Huang1, Yue Jia Choo1, Helen Elizabeth Smith1, Christian Apfelbacher2,3.
Abstract
Atopic dermatitis (AD) is a common chronic inflammatory skin condition which impacts psychological wellbeing and social relationships. There have been studies of AD's impact on quality of life (QoL) in Western countries, but these findings cannot be directly extrapolated to Asian populations with genetic, environmental and cultural differences. Therefore, we aimed to systematically review the literature pertaining to QoL impairment in AD in East and Southeast Asia to characterize the impact of AD on patients and their families, and to identify the factors affecting the degree of QoL impairment. A search of English language papers was conducted on MEDLINE, EMBASE, PSYCInfo, Global Health and Web of Science. Observational studies measuring QoL using single or multi-item instruments in people with self-reported or physician diagnosed atopic dermatitis were included. 27 studies from 29 articles were included and synthesized. There is data documenting QoL impairment in AD sufferers and their families, across a wide range of Asian countries, healthcare settings and ages. Aspects of QoL impacted to a greater extent included symptoms of itch, feelings of embarrassment, and sleep disturbance. Severity of disease affects the degree of impairment of QoL, but there is no apparent link between QoL impairment and patient demographic factors, or other medical factors such as age at diagnosis or duration of illness. Our findings also highlighted the need for clinicians to actively explore the impact of patient's symptoms, especially in an Asian context where healthcare communications are traditionally doctor-centric.Entities:
Keywords: Asian; Atopic dermatitis; Quality of life; Systematic review
Mesh:
Year: 2021 PMID: 34086064 PMCID: PMC9162971 DOI: 10.1007/s00403-021-02246-7
Source DB: PubMed Journal: Arch Dermatol Res ISSN: 0340-3696 Impact factor: 3.033
Inclusion/exclusion criteria
| Aspect of study | Criteria |
|---|---|
| Population | Included: people of any age group diagnosed with atopic dermatitis using any diagnostic criteria or self-reported diagnoses. Both population-based studies and studies using clinical samples were included |
| Study type | Included: observational studies Excluded: interventional studies, case reports, case series and studies which do not report primary data |
| Context | Included: studies of populations in East Asia or Southeast Asia Excluded: ethnic Asians living outside of Asia |
| Outcome | Included: studies which used single or multi-item instruments measuring QoL involving self or proxy reported data |
| Language | Included: English language papers only |
| Type of article | Included: journal articles only |
Fig. 1PRISMA flow diagram
Data extraction table of included studies, study and sample characteristics, and conclusions
| References | Study design, setting of study, sample size | Sample characteristics: age (mean ± standard deviation i.e. SD) or median (interquartile range), diagnosis severity | QoL instrument | Outcome values (mean ± SD) | Conclusions |
|---|---|---|---|---|---|
| Ang et al. [ | Cross sectional Patients from dermatology clinic 34 AD patients 16 below 5-years old (yo), 18 above 5-years old | Age = 5.3 ± 3.9 Diagnosis: not reported (NR) Severity: SCORe Atopic Dermatitis (SCORAD)—24 mild/mod, 30 severe | IDQoL and CDLQI | IDQoL = 6.8 ± 5.3 CDLQI = 8.8 ± 5.9 | QoL affected patients with severe AD patients more than those with mild/moderate severity ( Boys with AD were more impaired in participation in family activities than girls. Girls with AD had greater QoL impairment in social aspects, itching, mood change and sleep disturbance In children ≤ 4 years, mood disturbances were significantly affected in non-Chinese compared to Chinese ( |
| Arima et al. [ | Cross sectional Population survey 634 AD patients 1268 HCs | Age ≥ 18 years Diagnosis: patient reported physician diagnosis Severity: self rated—344 mild, 290 mod/severe | Japanese version 23 of SF-36v2 | SF-36 PCS = 52.04 (AD) vs 54.12 (HCs) ( SF-36 MCS = 42.29 (AD) vs 46.05 (HCs) ( SF-6D utility = 0.71 (AD) vs 0.76 (HCs) ( | Atopic dermatitis patients also reported significantly reduced QoL relative to non-AD controls in both mental and physical domains, and overall utility score Severity did not have statistically significant effect on QoL |
| Aziah et al. [ | Cross sectional Patients from dermatology clinic 33 AD patients 70 parents of AD patients | 0–16-years old, median = 74 months Diagnosis: Hanifin and Rajka criteria Severity: SCORAD = 38.9 ± 15.5 | DFI and CDLQI (Malay translated) | CDLQI = 10.0 ± 6.6, DFI = 9.4 ± 5.3 | There was a significant difference of the DFI scores between the moderate and severe atopic dermatitis ( Aspects of the DFI most affected were family diet, sleep loss, the parents’ emotional disturbance and their exhaustion Family impact was greater in severe AD vs moderate AD ( |
| Bae et al. [ | Cross sectional Military personnel 68 people with AD | Age = did not state specifically Diagnosis: clinical judgment base on criteria Severity: NR | Skindex-29 | Skindex-29 (95CI): symptom = 38.9 (32.1–46.1) Functional = 20.7 (12.5–28.9) Emotional = 27.8 (21.8–33.5) Overall = 29.1 (23.0–35.2) | NIL |
| Chen et al. [ | Cross sectional Nursing staff from a hospital 90 AD patients 837 HCs | Age: NR Diagnosis: Hanifin and Rajka criteria Severity: NR | SF-36 | QoL was significantly lower for patients with AD compared with controls in five out of eight domains, including—bodily pain, general health, mental health, vitality and social functioning | |
| Cheok et al. [ | Cross sectional Community-based, from a household survey 89 AD patients | Age: NR Diagnosis: U.K. Working Party Diagnostic Criteria Severity: clinical—clear: 45%, almost clear: 33%, mild: 13%, mod: 9% | EQ-5D weighted and VAS, DLQI | Not explicitly stated | A greater percentage of participants in AD reported suboptimal global health vs those without AD (89% vs 77.4%, Difference in QoL between mild and moderate AD patients was statistically significant in adult (> 18) patients but not in < 18-year-old patients |
| Chuh and Chan [ | Case–control study Patients in a primary care setting 22 AD patients | Age: NR Diagnosis: U.K. Working Party Diagnostic Criteria Severity: SCORAD = 18.14 ± 9.99 | DLQI | DLQI = 12.00 ± 5.38 | The main study population was pityriasis rosea patients, with AD patients as the control group QoL strongly correlated with SCORAD scores ( QOL was significantly more affected in patients with atopic dermatitis than in patients with pityriasis rosea or acne vulgaris |
| Ghani et al. [ | Cross sectional Patients from dermatology clinic 110 AD patients | Age: 5–18-years old. Median (IQR) = 9.0 (13.0)-years old Diagnosis: NR Severity: SCORAD—mild = 30.9%, moderate = 62.7%, severe = 6.4% | CDLQI, DFI | CDLQI = 8.0 DFI = 7.0 | Most affected items were itchiness, sleep loss, embarrassment and treatment difficulty Disease severity (as quantified by SCORAD) was the only significant associated factor (< 0.01). Social factors and medical factors besides severity did not significantly affect QoL Family impact: 2 items most affected were family expenditure and family diet |
| Higaki et al. [ | Cross sectional Patients from dermatology clinic 162 AD patients | Age = 29 ± 9 years Diagnosis: NR Severity: Rajka and Langeland criteria score = 6.5 ± 1.5 | Japanese version of Skindex-16 | Skindex-16 = 50 ± 23 | Patients with severe atopic dermatitis had significantly higher QOL impairment, including in symptoms, emotions and functioning Patients with atopic dermatitis significantly higher QOL impairment than patient with isolated lesions, particularly in symptoms and emotions |
| Ho et al. [ | Cross sectional Patients from dermatology center 104 AD patients | Age range 0–16-year old, mean = 6.4 ± 4.3 years Diagnosis: Hanifin and Rajka criteria Severity: SCORAD—value NR | IDLQI, CDLQI, SF-12, DFI | DFI = 7.2 ± 6.5, SF-12 PH = 52.7 ± 4.8, SF-12 MH = 49.7 ± 8.8 | The QoL, SF-12 PH, SF-12 MH, and DFIQ scores were significantly correlated with severity ( Family impact was correlated with quality of life (QoL) of AD patients ( Greatest causes of discomfort for infants were itching, sleep problems and influence of disease on mood. For children: itching, sleep problems, impact on swimming and sport and inconvenience because of treatment. Friendship is the least disturbing issue DFI items that were affected: for the mothers, the greatest problems in their physical and MH include (i) limitation of moderate activities such as housework, (ii) less accomplishment because of poor physical or emotional health, (iii) reduction of social activities like visiting friends and relatives |
| Hon et al. [ | Cross sectional Patients from dermatology clinic | Age range: 1–18 years, mean age: 10.8 ± 4.9 years Diagnosis: Hanifin and Rajka criteria Severity: POEM, SCORAD—value NR | CDLQI | Not explicitly stated | The Patient-Oriented Eczema Measure (POEM), objective SCORAD and CDLQI were correlated with each other |
| Hon et al. [ | Cross sectional Patients from dermatology clinic 126 AD patients | Age: < 18 years, mean = 11.4 ± 5.6 years Diagnosis: Hanifin and Rajka criteria Severity: POEM = 14.8 ± 7.3, NESS = 7.6 ± 3.4, SCORAD = 38.1 ± 18.2 | CDLQI | CDLQI = 9.8 ± 7.3 | CDLQI was negatively correlated with stratum corneum skin hydration ( QoL impairment was correlated with disease severity. Severity was independently associated with aspects such as pruritus, activities, sleep disturbance, friendship, bullying QoL was dependent on severity of symptoms, including bleeding, cracking and flaking of skin |
| Hon et al. [ | Cross sectional Setting: NR 133 AD patients | Age range: 5–16 years, Age = 11.0 (8.4–13.6) Diagnosis: Hanifin and Rajka criteria Severity: NESS, SCORAD | CDLQI | Not explicitly stated | QoL was correlated with severity of AD ( Severity and QoL scores did not differ between male and female patients, or between patients aged ≤ 10 years and those aged > 10 years ( Itch, sleep disturbance, treatment and swimming/sports were the four QoL issues that were most commonly affected |
| Hon et al. [ | Cross sectional Patients from dermatology clinic 9 AD patients, 4 HCs | Age: < 18 years, mean age (AD) = 11.6 (10.7–12.0) years age (HC) = 13.7 (13.3–14.0) years Diagnosis: Hanifin and Rajka criteria Severity: SCORAD—median = 60.7 | CDLQI | Not explicitly stated | CDLQI statistically significantly correlated with Fit 3 ligand, interleukin-8, macrophage inflammatory protein-3a levels |
| Hon et al. [ | Cross sectional Patients from a hospital 120 AD patients | Age = 16.0 (14.4–18.2) years Diagnosis: Hanifin and Rajka diagnostic criteria Severity: Nottingham Eczema Severity Score (NESS) | Chinese version of CDLQI | CDLQI: 8 (4–11) (AD) vs 1.5 (1.0–4.8) (control) ( | AD patients (median age 16-years old) had lower SH, higher trans-epidermal water loss, worse CDLQI, and reported higher overall, depressive and stress symptom scores |
| Hon et al. [ | Cross sectional Patients from dermatology clinic 157 AD patients | Age: mean = 10.15 Diagnosis: U.K. Working Party Diagnostic Criteria Severity: NESS—value NR | CDLQI | Not explicitly stated | QoL lower in patients with mild eczema vs patients with mod/severe eczema CDLQI was linked to severity, mother and father education and corticosteroid (CS) fear. There was also a correlation between CDLQI with use of oral traditional Chinese herbal medicine |
| Hon et al. [ | Cross sectional Patients from a hospital 142 AD patients | Age = 12.0 ± 5.0 years Diagnosis: Hanifin and Rajka diagnostic criteria Severity: NR | CDLQI | CDLQI = 8.2 ± 5.7 | NIL |
| Itakura et al. [ | Cross-sectional Patients from web-based population study 1668 AD patients | Age = 43.1 ± 10.6 Diagnosis: patient reported physician diagnosis Severity: NR | DLQI | DLQI = 4.8 ± 5.1 | Aspects of QoL most affected were “symptoms and feelings” and “daily activities”. “Treatment” was least affected |
| Jang et al. [ | Cross sectional Patients from a hospital 78 patients with AD 78 parents of patients with AD | Age: younger than 18-years old Parents = 37.4 ± 5.3 years Children = 65.1 ± 45.7 months Diagnosis: Hanifin and Rajka’s diagnostic criteria Severity: SCORAD = 28.3 ± 16.1 | Korean version of PedsQL 4.0, IDQoL, DLQI, DFI | IDQoL = 7.4 ± 5.2, 6.0 (1–23) CDLQI = 4.8 ± 3.6, 4.5 (0–14) DFI = 11.2 ± 6.0 PedsQL = 89.3 ± 9.5, 92.9 (65.2–100) | Patients with a higher severity of AD had 6.6 times ( Family QoL was more impacted in girls with AD than boys ( Parents’ life satisfaction was correlated with generic QoL and dermatology QoL of children Parents’ positive affect showed no statistically significant correlation with dermatology QoL of AD children, but parent’s negative affect and parenting stress showed a correlation |
| Kawashima et al. [ | Study 1 is cross sectional, study 2 is interventional (not included) Patients from multiple dermatology clinics 106 AD patients | Age = 26.3 ± 7.5 years Diagnosis: NR Severity: Rajka and Langeland—all with mod/severe AD | Japanese version of the WHOQOL-26; | WHOQoL-26 (AD) = 3.1 ± 0.5 vs. (HC) 3.3 ± 0.5, respectively; | QoL was worse for AD patients in areas of physical health, psychological and general wellbeing ( Among patients with AD, those with steroid phobia had a slightly lower QoL |
| Kim et al. [ | Longitudinal study Patients from multiple dermatology clinics 34 AD patients | Age = 15 ± 10 years Diagnosis: NR Severity: EASI, Rajka—values NR | EQ5D-Kor Korean EQ5D- Visual Analog Scale (EQ5D-VAS) | EQ5D-Kor = 0.7 ± 0.2 EQ5D-VAS = 64.1 ± 22.7 | EQ5D Kor score indicated a 30% decrease in QoL, while the visual analog scale indicated a 35% decrease in QoL Using EASI or Rajka, there was a statistically significant relationship between severity and QoL measurements |
| Kim et al. [ | Cross sectional study Patients from multiple dermatology clinics 415 AD patients: (71 infants, 197 children and 147 adults) | Age: 14.5 ± 10.8 Diagnosis: Hanifin and Rajka diagnostic criteria Severity: SCORAD infants = 15.8 ± 8.4, children = 16.6 ± 7.9, adults = 19.6 ± 10.0 Rajka: infants = 5.4 ± 1.9, children = 5.8 ± 1.9, adults = 6.2 ± 1.9 | IDQOL, CDLQI, DLQI for infant, children and adult, respectively | IDQoL = 7.7 ± 5.5, CDLQI = 6.6 ± 6.3, DLQI = 10.7 ± 7.9 | QoL measurements were not significantly affected by gender No significant differences in QoL between infants with AD alone and infants with AD and other concomitant atopic diseases Aspects of QoL most affected were symptoms, mood and sleep, while treatment and social ridicule were less problematic No significant difference in QoL between genders, age groups (5–10-year-old vs 11–16-year-old patients) or presence of concomitant atopic disease |
| Kwak et al. [ | Cross sectional Population survey 157 people with AD 11,756 HCs (Kwak et al.) 677 people with AD 36,901 HCs (Lee et al.) | Age: ≥ 19 years, mean = 35.2 ± 1.3 Diagnosis: patient reported Severity: NR | EQ 5D, VAS | EQ VAS (AD) = 70.6 ± 1.39 EQ VAS (HC) = 74.1 ± 0.22 | Significant difference in QoL between patients with AD and HCs ( QoL was reduced in AD using the EQ-VAS QoL instrument, but not when using the EQ5D AD impacted the “pain/discomfort” and “anxiety/depression” domains of EQ5D significantly |
| Lam et al. [ | Cross sectional Patients from multiple dermatology clinics 120 AD patients (50 adults and 70 children) 2410 HCs | Age: 3–65 years Mean age = 15 Diagnosis: UK Working Party’s diagnostic criteria Severity: SCORAD—value NR | > 16-year-old: 36-item SF-36 and (DLQI). 14–16 year-old: SF-36 and (CDLQI) Aged 3–14 year-old: CDLQI | CDLQI = 7.7 ± 6.0, DLQI = 10.1 ± 6.4, SF-36 PCS = 49.94 ± 8.98 (AD) vs 50.00 ± 10 (control), SF-36 MCS = 45.15 ± 11.28 (AD) vs 50.00 ± 10 (control) | All the SF-36 dimensions were lower than that of the HCs. QoL (as measured by Sf-36 and CDLQI/DLQI) was reduced in AD Symptoms and feelings, leisure, daily activities and sleep were aspects of QoL most affected QoL showed a statistically significant correlation with severity (p < 0.05) |
| Ng et al. [ | Cross sectional Recruited from a pediatric dermatology service 50 AD patients | Age: mean = 13.4 years Diagnosis: UK Working Party’s diagnostic criteria Severity: EASI—mild: 30%, mod: 36%, severe: 34% | CDLQI | CDLQI = 15.2 | Neither age, gender nor race impacted QoL Adolescent with severe AD had lower QoL scores than mild and mod 3 most affected domains were “leisure, physical activities”, “Skin itch and soreness” and “sleep interference” |
| Oh et al. [ | Cross sectional Setting: patients with AD 28 AD patients 28 age, sex matched HC | Age: mean (AD) = 24.1 years (age range 13–41) mean (HC) = 25.2 years (age range 12–43 years) Diagnosis: Hanifin and Rajka criteria Severity: EASI = 21.9 ± 12.7 (range 5.6–58) VAS for pruritus = 7.1 ± 1.5 (range 5–10) VAS for sleep loss = 5.3 ± 3.2 (range 0–10) | DLQI | Not explicitly stated | Statistically significant positive correlations were observed between QoL and various psychological scales (Beck Depression Inventory, State Anxiety, Trait Anxiety, Interaction Anxiousness Scale, and Private Body Scale) |
| Yano et al. [ | Cross sectional Patients from a hospital 112 AD patients | Age = 35.6 ± 10.8 years Diagnosis: NR Severity: SCORAD = 35.5 ± 21.9 | DLQI | DLQI = 7.8 ± 5.1 | Both total work productivity impairment (TWPI) and total activity impairment (TAI) scores were significantly correlated with the severity and QoL |
Questions were grouped under headings, and scores for each heading were calculated based on their component questions as specified by the creators of the respective questionnaires
| QoL measure | References | Symptoms and feelings | Leisure | Personal relationships | School/holidays/work | Treatment | Sleep | Daily activities |
|---|---|---|---|---|---|---|---|---|
| CDLQI | Kim DH et al. [ | 43% (1st) | 20% | 15% | 27% (3rd) | 27% (3rd) | 33% (2nd) | NA |
| Lam et al. [ | 33% (1st) | 17% | 0% | 17% | 33% (1st) | 33% (1st) | NA | |
| Ng et al. [ | 86% (2nd) | 94% (1st) | 48% | 27% | 23% | 78% (3rd) | NA | |
| Ghani [ | 43% (1st) | 19% | 15% | 27% | 37% (3rd) | 40% (2nd) | NA | |
| DLQI | Chuh and Chan [ | 63% (1st) | 39% | 21% | 27% | 48% (2nd) | NA | 40% (3rd) |
| Itakura et al. [ | 42% (1st) | 13% | 7% | 17% (3rd) | 17% | NA | 22% (2nd) | |
| Kim et al. [ | 60% (1st) | 38% (3rd) | 22% | 53% (2nd) | 30% | NA | 37% | |
| Lam et al. [ | 50% (1st) | 33% (2nd) | 17% | 33% (2nd) | 33% (2nd) | NA | 33% (2nd) |
The scores below are a percentage of the total score for each heading. For each study, the aspects were ranked and indicated in brackets for the top few scores
Risk of bias assessment
| References | Description of study populationa | Sampling method | Follow-up | Classification of exposure | Classification of outcomes |
|---|---|---|---|---|---|
| Ang et al. [ | B, C | Random | (−) | Secure records | Validated instrument |
| Arima et al. [ | A, B, C | Random | (−) | Self reported | Validated instrument |
| Aziah et al. [ | A, B, C | Random | (+) follow up > 80% | Secure records | Validated instrument |
| Bae et al. [ | A, C | Not random | (−) | Secure records | Validated instrument |
| Chen et al. [ | A, C | Not random | (−) | Secure records | Validated instrument |
| Cheok et al. [ | A, B, C | Random | (−) | Secure records | Validated instrument |
| Chuh and Chan et al. [ | A, B, C | Not random | (−) | Secure records | Validated instrument |
| Ghani et al. [ | A, B, C | Random | (−) | Secure records | Validated instrument |
| Higaki et al. [ | A, C | Random | (+) follow-up > 80% | Secure records | Validated instrument |
| Ho et al. [ | A, B, C | Random | (−) | Secure records | Validated instrument |
| Hon et al. [ | B, C | Not random | (−) | Secure records | Validated instrument |
| Hon et al. [ | A, B, C | Random | (−) | Secure records | Validated instrument |
| Hon et al. [ | A, C | Unclear | (−) | Secure records | Validated instrument |
| Hon et al. [ | A, B, C | Random | (−) | Secure records | Validated instrument |
| Hon et al. [ | A, B,C | Random | (−) | Secure records | Validated instrument |
| Hon et al. [ | A, B, C | Unclear | (−) | Secure records | Validated instrument |
| Hon et al. [ | A, B, C | Unclear | (−) | Secure records | Validated instrument |
| Itakura et al. [ | A, B, C | Random | (−) | Self reported | Validated instrument |
| Jang et al. [ | A, B, C | Unclear | (−) | Self reported | Validated instrument |
| Kawashima et al. [ | A, B, C | Unclear | (−) | Secure records | Validated instrument |
| Kim C et al. [ | A, C | Unclear | Unclear | Secure records | Validated instrument |
| Kim DH et al. [ | A, C | Unclear | (−) | Secure records | Validated instrument |
| Kwak et al. [ | A, C | Random | (−) | Self reported | Validated instrument |
| Lam et al. [ | A, B, C | Not random | (−) | Secure records | Validated instrument |
| Ng et al. [ | A, B, C | Unclear | (−) | Secure records | Validated instrument |
| Oh et al. [ | A | Unclear | (−) | Unclear | Validated instrument |
| Yano et al. [ | C | Unclear | (−) | Secure records | Validated instrument |
aCriteria for inclusion/exclusion of study population include: (A) clear definition of atopic dermatitis (B) demographics (C) setting